Brainomix, a pioneer in AI-powered imaging for stroke and lung fibrosis, has named Khush F. Mehta as its new Chair of the Board, succeeding Professor Jacqueline Hunter CBE. This appointment supports the company’s global growth strategy, bolstered by a £14M ($18M) Series C investment aimed at expanding its AI imaging solutions in the US and new markets.
Khush F. Mehta appointed Chair to lead Brainomix’s global expansion.
Brings 20+ years of healthcare and AI imaging leadership experience.
Follows £14M Series C funding to accelerate stroke platform growth.
Recent FDA clearance enhances Brainomix 360 platform’s capabilities.
Focuses on scaling AI solutions for stroke and lung fibrosis care.
Succeeds Professor Jacqueline Hunter after five years of leadership.
Khush F. Mehta, with over two decades of healthcare leadership, including his role as Chairman of Arterys (acquired by Tempus AI in 2022) and Chief Strategy Officer at Siemens Healthcare, steps in to guide Brainomix’s international expansion. “We are delighted to welcome Khush as Chair at a pivotal growth stage for Brainomix,” said Dr Michalis Papadakis, CEO and Co-Founder at Brainomix. “His extensive leadership across international markets, coupled with his deep expertise in healthcare AI, makes him an ideal Chair to help navigate our further global expansion.”
Brainomix’s Brainomix 360 Stroke platform has driven a 50% increase in mechanical thrombectomy rates, improving patient outcomes in over 300 hospitals across 20+ countries. Its e-Lung platform, FDA-cleared in May 2024, supports lung fibrosis diagnosis and partnerships with global pharma leaders. “Brainomix has developed one of the most clinically impactful AI platforms, with demonstrative real-world data showing a transformative effect on stroke care,” said Mehta. His leadership will prioritize scaling these solutions globally.
Under outgoing Chair Professor Jacqueline Hunter CBE, Brainomix doubled in size and secured widespread adoption of its stroke platform while expanding its e-Lung platform. “The past five years have been a very exciting time for Brainomix, as we successfully progressed from a start-up to an established scale-up,” said Hunter. The recent £14M Series C funding and FDA clearance for a patented feature in the Brainomix 360 platform further solidify its position in healthcare AI.
Mehta’s appointment aligns with Brainomix’s goal to deepen its US presence and explore new therapeutic areas. “I’m honored to support the company in its next chapter, as it expands into new geographies and therapeutic areas,” said Mehta. The retirement of Founder Director Andrew Barker, who helped transform Brainomix from an Oxford spinout to a market leader, marks the end of a foundational era as the company prepares for sustained global success.
Brainomix’s strategic appointment of Khush F. Mehta as Chair, combined with recent funding and regulatory achievements, positions it to lead the healthcare AI market. The company is set to enhance stroke and lung fibrosis care, delivering innovative solutions that improve patient outcomes worldwide.
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 20 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.